Dream Start Wakens Investor Hopes for Impression Healthcare

|

Published 09-NOV-2017 11:32 A.M.

|

3 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.


Click Here to View Latest Articles

An up-and-coming dental impression company, Impression Healthcare (ASX:IHL), has reached a milestone of its first 1,000 units sold. Impression is Australia’s largest ‘dental impression’ company, with a specific business model of enabling methods of DIY dentalcare, thereby prevent debilitating mouth-related problems such as bruxism at little to no cost.

Impression’s ‘Knight Guard’ product has attained registration by the Therapeutic Goods Administration (TGA) and has now reached total sales of 1,000 units, having been launched earlier this year in June. The milestone demonstrates Impression’s ability to successfully launch innovative and revenue-generative products, but also, validates its inherent ‘DIY-dentalcare’ model designed to empower end-users with the ability to treat various ailments without the need for a dentist.

Over the past five months, sales have increased by around 20% month-on-month, according to Impression, and have diversified its revenue stream significantly.

However IHL is still in its early stages of growth and investors should seek professional financial advice if considering this stock for their portfolio.

Furthermore, Impression says that in addition to growing sales, there has been an overall increase in the average value of each order.

impression healthcare

Impression’s disruptive ‘direct-to-consumer’ purchasing model provides consumers with a high-quality and more-affordable night guard for the treatment of bruxism (teeth grinding and clenching) without the need to be prescribed or fitted by a dentist.

One of its flagship products — The Knight Guard — meets a significant and growing demand for affordable and customised dental devices for bruxism and are manufactured by experienced dental technicians, based in Melbourne, Australia.

According to the Sleep Health Foundation, approximately 50% of Australia’s population experience occasional bruxism and is considered to be a regular problem for about 5% of the population.

Impression is adamant its product-range will continue to grow and develop to further suit the needs of its customers. The strong level of confidence is partly explained by the prohibitive cost of professional dentist consultations that can tally as high as $1,200 per visit, compared to Impression’s pricing range of $130-$230, for the treatment of the same underlying ailment such as bruxism.

For the time being, Impression has only gradually initiated its marketing, PR and advertising activities to promote its product range, admitting it has so far relied on “repeat customers and customer referrals” for the bulk of its growth. Impression’s product-range was recently featured on Channel 9 News and ‘The Morning Show’ on Channel 7, which has led to further public awareness of its market presence.

Impression CEO, Matt Weston, said, “The board is excited by the initial brand development of the Knight Guard and the growth trajectory thus far has been impressive as we continue to optimise our marketing strategy to hasten sales.

Matt Weston

“Our business model is disruptive to the traditional dental devices market and the price point and quality of The Knight Guard has helped us to drive sales”.

“Our continuing focus is to generate further brand awareness and to drive traffic to The Knight Guard website. The website conversion rate is currently 2.46% month-to-date but has had daily peaks up to 4.37% so it appears that marketing momentum continues to gain traction,” he added.



General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.

 

Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free

X